Success Metrics

Clinical Success Rate

84.0%

Based on 21 completed trials

Completion Rate

84%(21/25)

Active Trials

3(9%)

Results Posted

57%(12 trials)

Terminated

4(11%)

Phase Distribution

Ph phase_1

23%

Ph phase_2

49%

Ph phase_4

Ph early_phase_1

Ph not_applicable

23%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution35 total trials

Early Phase 1First-in-human

1(2.9%)

Phase 1Safety & dosage

8(22.9%)

Phase 2Efficacy & side effects

17(48.6%)

Phase 4Post-market surveillance

1(2.9%)

N/ANon-phased studies

8(22.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

21 of 28 finished

Non-Completion Rate

25.0%

7 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(21)

Terminated(7)

Other(2)

Detailed Status

Completed21

Terminated4

Recruiting3

Withdrawn3

Not yet recruiting2

unknown2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

84.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (2.9%)

Phase 18 (22.9%)

Phase 217 (48.6%)

Phase 41 (2.9%)

N/A8 (22.9%)

Trials by Status

terminated411%

not_yet_recruiting26%

completed2160%

unknown26%

recruiting39%

withdrawn39%

Recent Activity

3 active trials

Showing 5 of 35

completednot_applicable

Evaluating Metabolic and Anti-inflammatory Effect of Genistein on Post-myocardial Infarction Patients

NCT06689566

not_yet_recruitingphase_1

Exploring a Natural Solution for Childhood Obesity

NCT07033767

View all 35 trials

Clinical Trials (35)

Showing 20 of 35 trialsScroll for more

NCT07742514Not Applicable

Genistein, Equol, Cognitive Function and Mood: Acute. (GECFAMa)

Completed

NCT07742501Not Applicable

Genistein, Equol, Cognitive Function and Mood: Twelve-week. (GECFAMc)

Completed

NCT07385937Not Applicable

Effectiveness of Genistein in Mild Cognitive Impairment

Not Yet Recruiting

NCT06689566Not Applicable

Evaluating Metabolic and Anti-inflammatory Effect of Genistein on Post-myocardial Infarction Patients

Recruiting

NCT07033767Phase 1

Exploring a Natural Solution for Childhood Obesity

Not Yet Recruiting

NCT06634108Phase 1

Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy

Recruiting

NCT06895954Not Applicable

The Clinical Study on Isoflavone Genistein in Restructuring the Gut Microbiota of Hyperlipidemia Patients

Completed

NCT01489813Phase 2

Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment

Completed

NCT06501768Phase 1

Cardiovascular Genistein Therapy for Heart Failure Inflammation

Recruiting

NCT02624388Phase 2

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

Terminated

NCT00244933Phase 2

Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer

Completed

NCT02766478Phase 2

Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer

Terminated

NCT01982578Not Applicable

Genistein as a Possible Treatment for Alzheimer's Disease.

Completed

NCT00118040Phase 2

Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer

Completed

NCT00376948Phase 2

Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed

NCT00882765Phase 2

Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Withdrawn

NCT04105023Not Applicable

Genistein Stimulates Insulin Sensitivity Through Gut Microbiota

Completed

NCT01126879Phase 2

Genistein in Treating Patients With Prostate Cancer

Terminated

NCT00287690Phase 2

Isoflavones and the Coronary Circulation in Men and Women With Coronary Artery Disease

Completed

NCT01985763Phase 1

Genistein in Treatment of Metastatic Colorectal Cancer

Completed

Drug Details

Intervention Type: DIETARY SUPPLEMENT
Total Trials: 35